EUVIMEDEUVIMED entdecken
Validierungsstudie

Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab

Kazunari Tanaka iD, Kunihiko Tsuji iD, Atsushi Hiraoka iD, Toshifumi Tada iD, Masashi Hirooka iD, Kazuya Kariyama iD, Joji Tani iD, Masanori Atsukawa iD, Koichi Takaguchi, Ei Itobayashi iD, Shinya Fukunishi iD, Toru Ishikawa iD und 33 weitere

Liver International · 2025

DOI: 10.1111/liv.70286 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Liver International, 2025. Verfasst von Kazunari Tanaka und 44 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Bevacizumab, C-Reactive Protein, Antibodies, Monoclonal, Humanized, Liver Neoplasms. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim/Background This study aimed to validate the CLEAR score, a simple prognostic tool for hepatocellular carcinoma (HCC) patients undergoing atezolizumab plus bevacizumab (Atez/Bev) therapy, based on serum lactate dehydrogenase (LDH) and C‐reactive protein (CRP) levels. Materials/Methods From 2020 to 2023, 498 Japanese HCC patients receiving Atez/Bev therapy were enrolled. They were divided into a training set ( n = 280; 13 designated cancer care hospitals) and a validation set ( n = 218; 11 universities and their affiliated Japanese hospitals). In the training set, prognostic factors were analysed, leading to the development of the CLEAR score, which was then evaluated on the validation set.

Results

Baseline LDH beyond the upper normal limit (hazard ratio [HR] 1.97, 95% CI 1.48–2.64) and CRP (≥ 0.50 mg/dL) (HR 1.61, 95% CI 1.19–2.00) were identified as independent prognostic factors on multivariate analysis and used in the CLEAR score. In the training set, the median progression‐free survival (PFS) times in patients with scores 0, 1 and 2 were 11.1 months, 9.1 months and 3.3 months, respectively ( p < 0.001). The median overall survival (OS) times in patients with scores 0, 1 and 2 were not available, 15.3 months and 10.6 months, respectively ( p < 0.001). Similar results were obtained in the validation set (median PFS and OS times for scores 0, 1 and 2 = 9.4, 6.9 and 4.3 and 30.6, 20.8 and 8.9 months, respectively, each p < 0.001).

Conclusion

The CLEAR score provides a distinct and simple prediction of the prognosis of HCC patients receiving Atez/Bev therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabC-Reactive ProteinAntibodies, Monoclonal, HumanizedLiver NeoplasmsL-Lactate DehydrogenaseCarcinoma, HepatocellularAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedPrognosisJapanRetrospective Studies

Stichwörter der Autor:innen

C‐reactive proteinatezolizumab plus bevacizumabhepatocellular carcinomalactate dehydrogenaseprognostic predictive model

Substanzen

atezolizumabBevacizumabC-Reactive ProteinAntibodies, Monoclonal, HumanizedL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Department of Hepatology, Okayama City Hospital, Okayama, Japan.
  • Department of Gastroenterology and Hepatology, Kagawa University, Takamatsu, Japan.

ORCID-Profile: Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Ei Itobayashi, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hideko Ohama, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Tomoko Aoki, Hironori Ochi, Yuki Kanayama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Taeang Arai, Akemi Tsutsui, Hidenao Noritake, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

Zitieren

APA

Tanaka, K., Tsuji, K., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Ishikawa, T., Tajiri, K., Ohama, H., Toyoda, H., Ogawa, C., Nishimura, T., Hatanaka, T., Kakizaki, S., …, & Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) (2025). Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab. Liver International. https://doi.org/10.1111/liv.70286

Vancouver

Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al. Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab. Liver International. 2025. doi:10.1111/liv.70286

BibTeX
@article{Tanaka2025,
  author = {Tanaka, Kazunari and Tsuji, Kunihiko and Hiraoka, Atsushi and Tada, Toshifumi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Fukunishi, Shinya and Ishikawa, Toru and Tajiri, Kazuto and Ohama, Hideko and Toyoda, Hidenori and Ogawa, Chikara and Nishimura, Takashi and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Naganuma, Atsushi and Kosaka, Hisashi and Matono, Tomomitsu and Kuroda, Hidekatsu and Yata, Yutaka and Nishikawa, Hiroki and Imai, Michitaka and Aoki, Tomoko and Ochi, Hironori and Kanayama, Yuki and Tada, Fujimasa and Nakamura, Shinichiro and Nouso, Kazuhiro and Morishita, Asahiro and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Tsutsui, Akemi and Tanaka, Hironori and Noritake, Hidenao and Kaibori, Masaki and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi and Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)},
  title = {Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70286}
}
Kostenlos starten →